Medical Standards Crisis

A controversial standard for diabetes management, which promotes tightly controlled hemoglobin A1c levels, lacks substantial evidence of medical benefit. Despite findings indicating that aggressive treatment could increase mortality risk, the healthcare system remains entrenched in these practices, driven by profit motives from pharmaceutical companies. The conversation highlights the urgent need for a course correction in healthcare to prioritize prevention and overall well-being over costly medications.